Breast cancer microRNAs: Signaling networks and clinical applications

MicroRNAs in Cancer

Volumn , Issue , 2013, Pages 1-43

  Eades, Gabriel ^a   Yaob, Yuan ^a   Zhouc, Qun ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937694053     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14586     Document Type: Chapter

References (172)

1. Adachi, R., S. Horiuchi, Y. Sakurazawa, T. Hasegawa, K. Sato, and T. Sakamaki. 2011. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun. 411(4): 804-808.
2. Adams, B.D., H. Furneaux, and B.A. White. 2007. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 21(5): 1132-1147.
3. Adams, B.D., D.M. Cowee, and B.A. White. 2009. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-α (ERα) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol. 23(8): 1215-1230.
4. Al-Ejeh, F., C.E. Smart, B.J. Morrison, G. Chenevix-Trench, J.A. López, S.R. Lakhani et al. 2011. Breast cancer stem cells: Treatment resistance and therapeutic opportunities. Carcinogenesis. 32(5): 650-658.
5. Al-Nakhle, H., P.A. Burns, M. Cummings, A.M. Hanby, T.A. Hughes, S. Satheesha et al. 2010. Estrogen receptor β1 expression is regulated by miR-92 in breast cancer. Cancer Res. 70(11): 4778-4784.
6. Appaiah, H., C. Goswami, L. Mina, S. Badve, G. Sledge, Y. Liu et al. 2011. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 13(5): R86.
7. Arteaga, C.L., M.X. Sliwkowski, C.K. Osborne, E.A. Perez, F. Puglisi, and L. Gianni. 2012. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol. 9(1): 16-32.
8. Avraham, R., A. Sas-Chen, O. Manor, I. Steinfeld, R. Shalgi, G. Tarcic et al. 2010. EGF decreases the abundance of MicroRNAs that restrain oncogenic transcription factors. Sci Signal. 3(124): ra43.
9. Bachmann, I.M., O.J. Halvorsen, K. Collett, I.M. Stefansson, O. Straume, S.A. Haukaas et al. 2006. EZH2 expression is associated with high proliferation rate and aggressive tumorsubgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 24(2): 268-273.
10. Barbarotto, E., T.D. Schmittgen, and G.A. Calin. 2008. MicroRNAs and cancer: Profi le, profi le, profi le. Int J Cancer. 122(5): 969-977.
11. Bartel, D.P. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116(2): 281-297.
12. Baylin, S.B. 2005. DNA methylation and gene silencing in cancer. Nat Clin Prac Oncol. 2: S4.
13. Baylin, S.B. and P.A. Jones. 2011. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 11(10): 726-734.
14. Bergamaschi, A. and B.S. Katzenellenbogen. 2012. Tamoxifen downregulation of miR-451 increases 14-3-3[zeta] and promotes breast cancer cell survival and endocrine resistance. Oncogene . 31(1): 39-47.
15. Bhat-Nakshatri, P., G. Wang, N.R. Collins, M.J. Thomson, T.R. Geistlinger, J.S. Carroll et al. 2009. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 37(14): 4850-4861.
16. Bishop, J.A., H. Benjamin, H. Cholakh, A. Chajut, D.P. Clark, and W.H. Westra. 2010. Accurate classifi cation of Non-Small cell lung carcinoma using a novel MicroRNA-based approach. Clin Cancer Res. 16(2): 610-619.
17. Blenkiron, C., L. Goldstein, N. Thorne, I. Spiteri, S. Chin, M. Dunning et al. 2007. MicroRNA expression profi ling of human breast cancer identifi es new markers of tumor subtype. Genome Biol. 8(10): R214.
18. Borowsky, A.D. 2011. Choosing a mouse model: Experimental biology in Context-The utility and limitations of mouse models of breast cancer. Cold Spring Harb Perspect Biol. 3(9):a009670.
19. Buck, M.B. and C. Knabbe. 2006. TGF-beta signaling in breast cancer. Ann N Y Acad Sci. 1089(1): 119-126.
20. Buerger, H., F. Otterbach, R. Simon, K. Schäfer, C. Poremba, R. Diallo et al. 1999. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 189(4): 521-526.
21. Buffa, F.M., C. Camps, L. Winchester, C.E. Snell, H.E. Gee, H. Sheldon et al. 2011. microRNAassociated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profi ling in breast cancer. Cancer Res. 71(17): 5635-5645.
22. Burstein, H.J. and J.J. Griggs. 2010. Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 19(3): 639-647.
23. Calin, G.A., C. Sevignani, C.D. Dumitru, T. Hyslop, E. Noch, S. Yendamuri et al. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101(9): 2999-3004.
24. Calin, G.A. and C.M. Croce. 2006a. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66(15): 7390-7394.
25. Calin, G.A. and C.M. Croce. 2006b. MicroRNA signatures in human cancers. Nat Rev Cancer. 6(11): 857-866.
26. Camps, C., F.M. Buffa, S. Colella, J. Moore, C. Sotiriou, H. Sheldon et al. 2008. Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 14(5): 1340-1348.
27. Castellano, L., G. Giamas, J. Jacob, R.C. Coombes, W. Lucchesi, P. Thiruchelvam et al. 2009. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA. 106(37): 15732-15737.
28. Chang, S., R. Wang, K. Akagi, K. Kim, B.K. Martin, L. Cavallone et al. 2011. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 17(10): 1275-1282.
29. Chen, X., Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang et al. 2008. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10): 997-1006.
30. Chen, J., W. Tian, H. Cai, H. He, and Y. Deng. 2011. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. (in press).
31. Cimmino, A., G.A. Calin, M. Fabbri, M.V. Iorio, M. Ferracin, M. Shimizu et al. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102(39): 13944-13949.
32. Cittelly, D.M., P.M. Das, V.A. Salvo, J.P. Fonseca, M.E. Burow, and F.E. Jones. 2010. Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 31(12): 2049-2057.
33. City of Hope Medical Center. MIRNA profi ling of breast cancer in patients undergoing neoadjuvant or adjuvant treatment for locally advanced & infl ammatory breast cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Jan 27]. Available from http://clinicaltrials.gov/ct2/show/NCT01231386 NLM Identifi er: NCT01231386.
34. Cochrane, D.R., N.S. Spoelstra, E.N. Howe, S.K. Nordeen, and J.K. Richer. 2009. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 8(5): 1055-1066.
35. Cochrane, D.R., D.M. Cittelly, E.N. Howe, N.S. Spoelstra, E.L. McKinsey, K. LaPara et al. 2010. MicroRNAs link estrogen receptor alpha status and dicer levels in breast cancer. Horm Cancer. 1(6): 306-319.
36. Collett, K., G.E. Eide, J. Arnes, I.M. Stefansson, J. Eide, A. Braaten et al. 2006. Expression of enhancer of zeste homologue 2 is signifi cantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 12(4): 1168-1174.
37. de Souza, R.S., A. Breiling, N. Gupta, M. Malekpour, M. Youns, R. Omranipour et al. 2010. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor α in breast cancer cells. Cancer Res. 70(22): 9175-9184.
38. Dedes, K.J., R. Natrajan, M.B. Lambros, F.C. Geyer, M. Lopez-Garcia, K. Savage et al. 2011. Down-regulation of the miRNA master regulators drosha and dicer is associated with specifi c subgroups of breast cancer. Eur J Cancer. 47(1): 138-150.
39. Derfoul, A., A.H. Juan, M.J. Difilippantonio, N. Palanisamy, T. Ried, and V. Sartorelli. 2011. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the polycomb Ezh2 methyltransferase. Carcinogenesis. 32(11): 1607-1614.
40. Di Leva, G., P. Gasparini, C. Piovan, A. Ngankeu, M. Garofalo, C. Taccioli et al. 2010. MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer. J Natl Cancer Inst. 102(10): 706-721.
41. Duan, R., C. Pak, and P. Jin. 2007. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 16(9): 1124-1131.
42. Eades, G., Y. Yao, M. Yang, Y. Zhang, S. Chumsri, and Q. Zhou. 2011. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 286(29): 25992-26002.
43. Esteller, M. 2008. Epigenetics in cancer. N Engl J Med. 358(11): 1148-1159.
44. Fabbri, M., R. Garzon, A. Cimmino, Z. Liu, N. Zanesi, E. Callegari et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 104(40): 15805-15810.
45. Foekens, J.A., A.M. Sieuwerts, M. Smid, M.P. Look, V. de Weerd, A.W.M. Boersma et al. 2008. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptorpositive human breast cancer. Proc Natl Acad Sci USA. 105(35): 13021-13026.
46. Foley, J., N.K. Nickerson, S. Nam, K.T. Allen, J.L. Gilmore, K.P. Nephew et al. 2010. EGFR signaling in breast cancer: Bad to the bone. Semin Cell Dev Biol. 21(9): 951-960.
47. Frasor, J., E.C. Chang, B. Komm, C. Lin, V.B. Vega, E.T. Liu et al. 2006. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 66(14): 7334-7340.
48. Friedman, R.C., K.K. Farh, C.B. Burge, and D.P. Bartel. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1): 92-105.
49. Garzon, R., S. Liu, M. Fabbri, Z. Liu, C.E.A. Heaphy, E. Callegari et al. 2009. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 113(25): 6411-6418.
50. Giricz, O., P.A. Reynolds, A. Ramnauth, C. Liu, T. Wang, L. Stead et al. 2012. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol. 226(1): 108-119.
51. Giuliano, M., R. Schifp, C.K. Osborne, and M.V. Trivedi. 2011. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 20: S42-S49.
52. Gong, C., Y. Yao, Y. Wang, B. Liu, W. Wu, J. Chen et al. 2011. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 286(21): 19127-19137.
53. Gonzalez-Angulo, A.M., F. Morales-Vasquez, and G.N. Hortobagyi. 2007. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 608: 1-22.
54. Guo, B., Y. Feng, R. Zhang, L. Xu, M. Li, H. Kung et al. 2011. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 10(1): 10.
55. Hannafon, B., P. Sebastiani, l.M. de, J. Lu, and C. Rosenberg. 2011. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 13(2): R24.
56. Hekman, M., S. Albert, A. Galmiche, U.E.E. Rennefahrt, J. Fueller, A. Fischer et al. 2006. Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding. J Biol Chem. 281(25): 17321-17336.
57. Heldring, N., A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman et al. 2007. Estrogen receptors: How do they signal and what are their targets. Physiol Rev. 87(3): 905-931.
58. Heneghan, H.M., N. Miller, R. Kelly, J. Newell, and M.J. Kerin. 2010a. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 15(7): 673-682.
59. Heneghan, H.M., N. Miller, A.J. Lowery, K.J. Sweeney, J. Newell, and M.J. Kerin. 2010b. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251(3): 499-505.
60. Holbro, T., R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas, and N.E. Hynes. 2003. The ErbB2/ ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 100(15): 8933-8938.
61. Hoover, R.N., M. Hyer, R.M. Pfeiffer, E. Adam, B. Bond, A.L. Cheville et al. 2011. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med. 365(14): 1304-1314.
62. Hossain, A., M.T. Kuo, and G.F. Saunders. 2006. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 26(21): 8191-8201.
63. Hsu, P., D.E. Deatherage, B.A.T. Rodriguez, S. Liyanarachchi, Y. Weng, T. Zuo et al. 2009. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res. 69(14): 5936-5945.
64. Huang, T., F. Wu, G.B. Loeb, R. Hsu, A. Heidersbach, A. Brincat et al. 2009. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem. 284(27): 18515-18524.
65. Iliopoulos, D., M. Lindahl-Allen, C. Polytarchou, H.A. Hirsch, P.N. Tsichlis, and K. Struhl. 2010. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Molecular Cell. 39(5): 761-772.
66. Iorio, M.V., M. Ferracin, C. Liu, A. Veronese, R. Spizzo, S. Sabbioni et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16): 7065-7070.
67. Iorio, M.V., P. Casalini, C. Piovan, G. Di Leva, A. Merlo, T. Triulzi et al. 2009. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69(6): 2195-2200.
68. Iyevleva, A., E. Kuligina, N. Mitiushkina, A. Togo, Y. Miki, and E. Imyanitov. 2011. High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. Breast Cancer Res Treat. 131(3): 1049-1059.
69. Johnston, S.R.D. and M. Dowsett. 2003. Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer. 3(11): 821-831.
70. Jones, K.L. and A.U. Buzdar. 2004. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer. 11(3): 391-406.
71. Jovanovic, J., J.A. Ronneberg, J. Tost, and V. Kristensen. 2010. The epigenetics of breast cancer. Mol Oncol. 4(3): 242-254.
72. Kim, V.N. 2005. MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol. 6(5): 376-385.
73. Kim, S., J. Oh, J. Shin, K. Lee, K.W. Sung, S.J. Nam et al. 2011. Development of microRNA-145 for therapeutic application in breast cancer. J Controlled Release. 155(3): 427-434.
74. Kondo, N., T. Toyama, H. Sugiura, Y. Fujii, and H. Yamashita. 2008. miR-206 expression is down-regulated in estrogen receptor α Positive human breast cancer. Cancer Res. 68(13): 5004-5008.
75. Kovalchuk, O., V.P. Tryndyak, B. Montgomery, A. Boyko, K. Kutanzi, F. Zemp et al. 2007. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifi cations, and aberrant microRNA expression. Cell Cycle. 6(16): 2010-2018.
76. Kovalchuk, O., J. Filkowski, J. Meservy, Y. Ilnytskyy, V.P. Tryndyak, V.F. Chekhun et al. 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7(7): 2152-2159.
77. Kozomara, A. and S. Griffiths-Jones. 2011. miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39: D152-D157.
78. Lakhani, S.R. 1999. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol. 187(3): 272-278.
79. Leaderer, D., A.E. Hoffman, T. Zheng, A. Fu, J. Weidhaas, T. Paranjape et al. 2011. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2(1): 9-18.
80. Lebanony, D., H. Benjamin, S. Gilad, M. Ezagouri, A. Dov, K. Ashkenazi et al. 2009. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non small-cell lung carcinoma. J Clin Oncol. 27(12): 2030-2037.
81. Lee, Y., J. Lee, C. Ho, Q. Hong, S. Yu, C. Tzeng et al. 2011. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res. 13(6): R116.
82. Lehmann, U., B. Hasemeier, M. Christgen, M. Müller, D. Römermann, F. Länger et al. 2008. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 214(1): 17-24.
83. Leivonen, S., R. Makela, P. Ostling, P. Kohonen, S. Haapa-Paananen, K. Kleivi et al. 2009. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 28(44): 3926-3936.
84. Li, W., R. Duan, F. Kooy, S.L. Sherman, W. Zhou, and P. Jin. 2009. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 46(5): 358-360.
85. Li, X., S. Mertens-Talcott, S. Zhang, K. Kim, J. Ball, and S. Safe. 2010. MicroRNA-27a indirectly regulates estrogen receptor α expression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology. 151(6): 2462-2473.
86. Li, D., Y. Zhao, C. Liu, X. Chen, Y. Qi, Y. Jiang et al. 2011. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 17(7): 1722-1730.
87. Linggi, B. and G. Carpenter. 2006. ErbB receptors: New insights on mechanisms and biology. Trends Cell Biol. 16(12): 649-656.
88. Lodygin, D., V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, H. Körner et al. 2008. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 7(16): 2591-2600.
89. Lu, Y., S. Roy, G. Nuovo, B. Ramaswamy, T. Miller, C. Shapiro et al. 2011. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem. 286(49): 42292-42302.
90. Lujambio, A., S. Ropero, E. Ballestar, M.F. Fraga, C. Cerrato, F. Setién et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67(4): 1424-1429.
91. Ma, L., J. Teruya-Feldstein, and R.A. Weinberg. 2007. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449(7163): 682-688.
92. Ma, L., F. Reinhardt, E. Pan, J. Soutschek, B. Bhat, E.G. Marcusson et al. 2010. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotech. 28(4): 341-347.
93. Mackiewicz, M., K. Huppi, J. Pitt, T. Dorsey, S. Ambs, and N. Caplen. 2011. Identifi cation of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 130(2): 663-679.
94. Maillot, G., M. Lacroix-Triki, S. Pierredon, L. Gratadou, S. Schmidt, V. Bénès et al. 2009. Widespread estrogen-dependent repression of microRNAs involved in breast tumor cell growth. Cancer Res. 69(21): 8332-8340.
95. Manavalan, T.T., Y. Teng, S.N. Appana, S. Datta, T.S. Kalbfleisch, Y. Li et al. 2011. Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifenresistant LY2 human breast cancer cells. Cancer Letters. 313(1): 26-43.
96. Masri, S., Z. Liu, S. Phung, E. Wang, Y. Yuan, and S. Chen. 2010. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 124(1): 89-99.
97. Masters, S.C., H. Yang, S.R. Datta, M.E. Greenberg, and H. Fu. 2001. 14-3-3 inhibits bad-induced cell death through interaction with serine-136. Mol Pharmacol. 60(6): 1325-1331.
98. Mattie, M., C. Benz, J. Bowers, K. Sensinger, L. Wong, G. Scott et al. 2006. Optimized highthroughput microRNA expression profi ling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 5(1): 24.
99. Meng, F., R. Henson, H. Wehbe-Janek, K. Ghoshal, S.T. Jacob, and T. Patel. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133(2): 647-658.
100. Miller, T.E., K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C.L. Shapiro et al. 2008. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 283(44): 29897-29903.
101. Miyoshi, K., T. Miyoshi, and H. Siomi. 2010. Many ways to generate microRNA-like small RNAs: Non-canonical pathways for microRNA production. Mol Genet Genomics. 284(2): 95-103.
102. Moasser, M.M. 2007. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 26(45): 6469-6487.
103. Neves, R., C. Scheel, S. Weinhold, E. Honisch, K. Iwaniuk, H. Trompeter et al. 2010. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes. 3(1): 219.
104. Nicoloso, M.S., H. Sun, R. Spizzo, H. Kim, P. Wickramasinghe, M. Shimizu et al. 2010. Singlenucleotide polymorphisms inside MicroRNA target sites infl uence tumor susceptibility. Cancer Res. 70(7): 2789-2798.
105. Noonan, E.J., R.F. Place, D. Pookot, S. Basak, J.M. Whitson, H. Hirata et al. 2009. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 28(14): 1714-1724.
106. O’Driscoll, L. and M. Clynes. 2006. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets. 6(5): 365-384.
107. Osborne, C.K. and R. Schiff. 2011. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62(1): 233-247.
108. Pandey, D.P. and D. Picard. 2009. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor α mRNA. Mol Cell Biol. 29(13): 3783-3790
109. Persson, H., A. Kvist, N. Rego, J. Staaf, J. Vallon-Christersson, L. Luts et al. 2011. Identifi cation of new MicroRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res. 71(1): 78-86.
110. Pigati, L., S.C.S. Yaddanapudi, R. Iyengar, D. Kim, S.A. Hearn, D. Danforth et al. 2010. Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS ONE. 5(10): e13515.
111. Png, K.J., M. Yoshida, X.H. Zhang, W. Shu, H. Lee, A. Rimner et al. 2011. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 25(3): 226-231.
112. Pogribny, I.P., J.N. Filkowski, V.P. Tryndyak, A. Golubov, S.I. Shpyleva, and O. Kovalchuk. 2010. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 127(8): 1785-1794.
113. Radojicic, J., A. Zaravinos, T. Vrekoussis, M. Kafousi, D.A. Spandidos, and E.N. Stathopoulos. 2011. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 10(3): 507.
114. Radpour, R., Z. Barekati, C. Kohler, M.M. Schumacher, T. Grussenmeyer, P. Jenoe et al. 2011. Integrated epigenetics of human breast cancer: Synoptic investigation of targeted genes, MicroRNAs and proteins upon demethylation treatment. PLoS ONE. 6(11): e27355.
115. Rajewsky, N. 2006. microRNA target predictions in animals. Nat Genet. 38: S8-S13.
116. Rao, X., G. Di Leva, M. Li, F. Fang, C. Devlin, C. Hartman-Frey et al. 2011. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene . 30(9): 1082-1097.
117. Rask, L., E. Balslev, S. Jorgensen, J. Eriksen, H. Flyger, S. Moller et al. 2011. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS. 119(10): 663-673.
118. Richly, H., L. Aloia, and L. Di Croce. 2011. Roles of the polycomb group proteins in stem cells and cancer. Cell Death and Dis. 2: e204.
119. Rigoutsos, I. 2009. New tricks for animal MicroRNAs: Targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res. 69(8): 3245-3248.
120. Rosenfeld, N., R. Aharonov, E. Meiri, S. Rosenwald, Y. Spector, M. Zepeniuk et al. 2008. MicroRNAs accurately identify cancer tissue origin. Nat Biotech. 26(4): 462-469.
121. Roth, C., B. Rack, V. Muller, W. Janni, K. Pantel, and H. Schwarzenbach. 2010. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12(6): R90.
122. Rothé, F., M. Ignatiadis, C. Chaboteaux, B. Haibe-Kains, N. Kheddoumi, S. Majjaj et al. 2011. Global MicroRNA expression profi ling identifi es MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE. 6(6):e20980.
123. Sabnis, G., A. Schayowitz, O. Goloubeva, L. Macedo, and A. Brodie. 2009. Trastuzumab reverses letrozole resistance and amplifi es the sensitivity of breast cancer cells to estrogen. Cancer Res. 69(4): 1416-1428.
124. Sachdeva, M., S. Zhu, F. Wu, H. Wu, V. Walia, S. Kumar et al. 2009. p53 represses c-myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 106(9): 3207-3212.
125. Sachdeva, M. and Y. Mo. 2010. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 70(1): 378-387.
126. Santaris Pharma A/S. Multiple ascending dose study of miravirsen in treatment-naïve chronic hepatitis C subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2012 Jan 27]. Available from http://clinicaltrials.gov/ct2/ show/NCT01200420 NLM Identifi er: NCT01200420.
127. Scott, G.K., A. Goga, D. Bhaumik, C.E. Berger, C.S. Sullivan, and C.C. Benz. 2007. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 282(2): 1479-1486
128. Sempere, L.F., M. Christensen, A. Silahtaroglu, M. Bak, C.V. Heath, G. Schwartz et al. 2007. Altered MicroRNA expression confi ned to specifi c epithelial cell subpopulations in breast cancer. Cancer Res. 67(24): 11612-11620.
129. Sempere, L.F., M. Preis, T. Yezefski, H. Ouyang, A.A. Suriawinata, A. Silahtaroglu et al. 2010. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res. 16(16): 4246-4255.
130. Shimono, Y., M. Zabala, R.W. Cho, N. Lobo, P. Dalerba, D. Qian et al. 2009. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 138(3): 592-603.
131. Shin, I., T. Miller, and C.L. Arteaga. 2006. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res. 12(3): 1008s-1012s.
132. Shoushtari, A.N., A.M. Michalowska, and J.E. Green. 2007. Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profi ling. Breast Dis. 28(1): 39-51.
133. Siegel, R., E. Ward, O. Brawley, and A. Jemal. 2011. Cancer statistics, 2011. CA Cancer J Clin. 61(4): 212-236.
134. Simpson, P.T., J. Reis-Filho, T. Gale, and S.R. Lakhani. 2005. Molecular evolution of breast cancer. J Pathol. 205(2): 248-254.
135. Sonoki, T., E. Iwanaga, H. Mitsuya, and N. Asou. 2005. Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia. 19(11): 2009-2010.
136. Sotiriou, C. and L. Pusztai. 2009. Gene-expression signatures in breast cancer. N Engl J Med. 360(8): 790-800.
137. Spizzo, R., M.S. Nicoloso, L. Lupini, Y. Lu, J. Fogarty, S. Rossi et al. 2009. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-[alpha] in human breast cancer cells. Cell Death Differ. 17(2): 246-254.
138. Steeg, P.S. 2006. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12(8): 895-904.
139. Steelman, L.S., P.M. Navolanic, M.L. Sokolosky, J.R. Taylor, B.D. Lehmann, W.H. Chappell et al. 2008. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 27(29): 4086-4095.
140. Stengel, C., S.P. Newman, M.P. Leese, B.V.L. Potter, M.J. Reed, and A. Purohit. 2009. Class III [beta]-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 102(2): 316-324.
141. Stern, D.F. 2003. ErbBs in mammary development. Exp Cell Res. 284(1): 89-98.
142. Stingl, J. 2011. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer. 2(2): 85-90.
143. Thomas, C. and J. Gustafsson. 2011. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 11(8): 597-608.
144. Tommasi, S., A. Mangia, R. Lacalamita, A. Bellizzi, V. Fedele, A. Chiriatti et al. 2007. Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins. Int J Cancer. 120(10): 2078-2085.
145. Tsai, H. and S.B. Baylin. 2011. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 21(3): 502-517.
146. Vargo-Gogola, T. and J.M. Rosen. 2007. Modelling breast cancer: One size does not fi t all. Nat Rev Cancer. 7(9): 659-672.
147. Vrba, L., J.C. Garbe, M.R. Stampfer, and B.W. Futscher. 2011. Epigenetic regulation of normal human mammary cell type-specifi c miRNAs. Genome Res. 21(12): 2026-2037.
148. Wang, V. and W. Wu. 2009. MicroRNA-based therapeutics for cancer. BioDrugs. 23(1): 15-23.
149. Wang, F., Z. Zheng, J. Guo, and X. Ding. 2010. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 119(3): 586-593.
150. Wang, Z., B. Lu, H. Wang, Z. Cheng, and Y. Yin. 2011. MicroRNA-21 modulates chemosensitivity of breast cancer cells to Doxorubicin by targeting PTEN. Arch Med Res. 42(4): 281-290.
151. Webster, R.J., K.M. Giles, K.J. Price, P.M. Zhang, J.S. Mattick, and P.J. Leedman. 2009. Regulation of epidermal growth factor receptor signaling in human cancer cells by MicroRNA-7. J Biol Chem. 284(9): 5731-5741.
152. Westholm, J.O. and E.C. Lai. 2011. Mirtrons: microRNA biogenesis via splicing. Biochimie. 93(11): 1897-1904.
153. Whiteside, T.L. 2008. The tumor microenvironment and its role in promoting tumor growth. Oncogene . 27(45): 5904-5912.
154. Wu, M., N. Jolicoeur, Z. Li, L. Zhang, Y. Fortin, D. L’Abbe et al. 2008. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis. 29(9): 1710-1716.
155. Wu, Q., Z. Lu, H. Li, J. Lu, L. Guo, and Q. Ge. 2011. Next-generation sequencing of MicroRNAs for breast cancer detection. J Biomed Biotechnol. (in press).
156. Xiong, J., D. Yu, N. Wei, H. Fu, T. Cai, Y. Huang et al. 2010. An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples. FEBS J. 277(7): 1684-1694.
157. Xu, N., T. Papagiannakopoulos, G. Pan, J.A. Thomson, and K.S. Kosik. 2009. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 137(4): 647-658.
158. Xu, J., X. Zhou, and C. Wong. 2011. Genome-wide identifi cation of estrogen receptor alpha regulated miRNAs using transcription factor binding data. In: Bioinformatics - Trends and Methodologies. InTech. 559-574.
159. Yager, J.D. and N.E. Davidson. 2006. Estrogen carcinogenesis in breast cancer. N Engl J Med. 354(3): 270-282.
160. Yamagata, K., S. Fujiyama, S. Ito, T. Ueda, T. Murata, M. Naitou et al. 2009. Maturation of MicroRNA is hormonally regulated by a nuclear receptor. Mol Cell. 36(2): 340-347.
161. Yu, Z., C. Wang, M. Wang, Z. Li, M.C. Casimiro, M. Liu et al. 2008. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol. 182(3): 509-517.
162. Yu, F., Y. Jiao, Y. Zhu, Y. Wang, J. Zhu, X. Cui et al. 2012. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem. 287(1): 465-473.
163. Zhang, L., J. Huang, N. Yang, J. Greshock, M.S. Megraw, A. Giannakakis et al. 2006. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 103(24): 9136-9141.
164. Zhang, Y., L. Yan, Q. Wu, Z. Du, J. Chen, D. Liao et al. 2011a. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 71(10): 3552-3562.
165. Zhang, B., X. Liu, J. He, C. Zhou, M. Guo, M. He et al. 2011b. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 32(1): 2-9.
166. Zhang, L., Y. Liu, F. Song, H. Zheng, L. Hu, H. Lu et al. 2011c. Functional SNP in the microRNA-367 binding site in the 3‘UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcifi cation. Proc Natl Acad Sci USA. 108(33): 13653-13658.
167. Zhao, J., J. Lin, H. Yang, W. Kong, L. He, X. Ma et al. 2008. MicroRNA-221/222 negatively regulates estrogen Receptor α and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 283(45): 31079-31086
168. Zhao, H., J. Shen, L. Medico, D. Wang, C.B. Ambrosone, and S. Liu. 2010. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 5(10): e13735.
169. Zhao, Y., C. Deng, J. Wang, J. Xiao, Z. Gatalica, R. Recker et al. 2011. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 127(1): 69-80.
170. Zhou, M., Z. Liu, Y. Zhao, Y. Ding, H. Liu, Y. Xi et al. 2010. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 285(28): 21496-21507.
171. Zhu, M., M. Yi, C.H. Kim, C. Deng, Y. Li, D. Medina et al. 2011a. Integrated miRNA and mRNA expression profi ling of mouse mammary tumor models identifi es miRNA signatures associated with mammary tumor lineage. Genome Biol. 12(8): R77.
172. Zhu, Y., F. Yu, Y. Jiao, J. Feng, W. Tang, H. Yao et al. 2011b. Reduced miR-128 in breast Tumor-Initiating cells induces chemotherapeutic resistance via bmi-1 and ABCC5. Clin Cancer Res. 17(22): 7105-7115.